Compare Eli Lilly And Co (LLY) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Otis Worldwide Corp — how do they compare? Eli Lilly And Co trades at $1,165.39 (market cap $1.02T), while Otis Worldwide Corp trades at $72.33 (market cap $28.20B). The key difference: Eli Lilly And Co is far larger — about 36.2× Otis Worldwide Corp's market cap, and Otis Worldwide Corp pays the higher dividend (2.31%). Which is the better fit depends on your goals.
| LLY | OTIS | |
|---|---|---|
Market Cap | $1.02T | $28.20B |
Sector | Health | Industrials |
52-Week High | $1.24K | $100.99 |
52-Week Low | $625.65 | $69.34 |
Enterprise Value | $1.06T | $35.58B |
Dividend Yield | 0.6% | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Otis Worldwide trades at $73.49, showing minimal daily movement with a slight 0.05% gain. The stock maintains a bullish technical signal, supported by moving averages, while oscillators remain neutral. Recent earnings have been mixed, with Q1 2026 missing estimates despite service growth. The company continues strategic initiatives, including dividend increases and modernization projects, as highlighted in recent corporate announcements.
Outlook remains cautiously optimistic with a consensus price target of $91, offering significant upside. Risks include margin pressures from tariffs and regional delays, but strong service revenue growth and a reasonable valuation provide a foundation for recovery. Investors should weigh near-term headwinds against long-term operational strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
